Sarcomatoid renal cell carcinoma (RCC) is difficult to treat and has long been associated with a poor prognosis. Also, the biology of sarcomatoid RCC has remained obscure. Scientists have tried to determine the molecular profile of sarcomatoid RCC and investigate different targeted therapies for genes such as TP53, BAP1, cell cycle, and chromatin-remodelling genes. Investigation of […]
The past decade or so has seen the development of multiple targeted therapies for metastatic renal cell carcinoma (RCC), such as vascular endothelial growth factor (VEGF) inhibitors and inhibitors of the mammalian target of the rapamycin (mTOR) pathway. Most recently, immune checkpoint inhibitors have been shown to have excellent clinical efficacy. Although patients are living […]
Scientists at the Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard and Dana-Farber Cancer Institute in the USA have tested thousands of non-cancer medicines in hundreds of different types of cancer cell in the laboratory to see if they can be used to treat cancer. They tested drugs that are currently licensed to […]
Scientists from the University of Cardiff have discovered part of our immune system that could potentially be harnessed to treat all types of cancer. This potential treatment has not yet been tested in humans, but has been shown to kill prostate, breast, lung and other cancers in the laboratory. Researchers suggest that the treatment has […]
A recent review of the use of immune checkpoint inhibitors for the treatment of metastatic renal cell carcinoma (RCC) was published in European Urology Focus this month. The use of immune checkpoint inhibitors has revolutionised the treatment of metastatic RCC over recent years. However, the appropriate duration of treatment with immune checkpoint inhibitors, such as […]
In this video interview, Brenda Martone discusses the clinical nurse specialist’s role in assessing and managing immune-related complications and toxicities associated with immune checkpoint inhibitors, such as nivolumab, ipilimumab and pembrolizumab. Brenda notes that immune-related reactions may occur months after a single dose of the immune checkpoint inhibitors. Immune-related reactions may include diarrhoea and colitis, […]
In 2015, the standard treatment for most patients with advanced kidney cancer was a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) such as sunitinib or pazopanib for untreated patients, followed by a checkpoint inhibitor (PD-1 inhibitor) such as nivolumab for patients who fail treatment with a VEGF inhibitor. However, over the last several […]
Over the past couple of years there have been several approvals of new treatments and drug combinations for advanced/metastatic renal cell carcinoma (RCC) resulting in treatment plans that are tailored for the individual patient. Recent advances in the treatment of advanced/metastatic RCC include cabozantinib, nivolumab/ipilimumab, pembrolizumab/axitinib and avelumab/axitinib. Dr Ajjai Shivaram Alva, associate professor at […]
Immune checkpoint inhibitors (ICIs), such as nivolumab and ipilimumab have revolutionised the treatment for metastatic renal cell carcinoma (RCC). However, the most appropriate duration for immunotherapy treatment is not clear. In a recent analysis of the results from the phase III CheckMate 214 trial, all RCC patients randomised to receive the nivolumab/ipilimumab combination had longer […]
In this interview with OncLive, Dr Ulka Vaishampayan from Wayne State University in Detroit, USA discusses the immunotherapy combinations that have been approved for first line treatment of metastatic renal cell carcinoma (mRCC) over the past year or so, and the need to identify biomarkers that can guide treatment selection for these patients. The combination […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
